Programme
Accelerate Alumni (Cohort 11)
Founded in
2016
Total funds raised
£124 million
Employees
101-250
Industry
Healthcare, pharma, biotech
bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy.
The company applies a patented safe harbour gene-targeting approach to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types.
The company has expertise in the underpinning science of synthetic biology and stem cells and also in manufacturing, and clinical translation.
The board is chaired by serial entrepreneur Dr Hermann Hauser and includes Sir Gregory Winter (Nobel Prize for medicine), biotech veteran Alan Roemer (co-founder Roivant and Pharmasset) and the company’s CEO and scientific founder Dr Mark Kotter.
Get in touch
News about bit.bio
Research centre news
Entrepreneurship Centre startups finalists in 2024 Science & Tech awards
Many alumni and startups of Cambridge Judge Entrepreneurship Centre programmes have been named finalists in the Cambridge Independent Science and Technology Awards 2024.
Research centre news
Who won at the Cambridge Independent Science and Technology Awards?
Several firms connected to Cambridge Judge Business School are honoured at the Cambridge Independent Science and Technology Awards.
Entrepreneurship and innovation
Venturing forth: bit.bio – reprogramming stem cells to allow manufacture of human cells
Biotech firm bit.bio, which was on the Accelerate Cambridge programme at Cambridge Judge Business School, reprograms stem cells to allow manufacture of human cells.
Press coverage on bit.bio
Business Weekly | 19 December 2024
Milner steps into CEO role as bit.bio unveils $30m funding
bit.bio, a Cambridge-based global leader in cell programming technology, has closed another significant growth funding round and changes at the top of management.
bit.bio | 16 December 2024
bit.bio raises $30 million led by M&G Investments
bit.bio, the global leader in cell programming technology, today announced the successful closing of a $30 million financing round led by M&G Investments, a leading international savings and investment company. Existing investors, including ARCH Venture Partners, BlueYard Capital, Milky Way, Puhua Capital, and Tencent, participated in the round.